DCPH:NSD-Deciphera Pharmaceuticals LLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 25.59

Change

0.00 (0.00)%

Market Cap

USD 2.21B

Volume

1.60M

Analyst Target

USD 73.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

N/A

USD 13.17B
VTRS Viatris Inc

N/A

USD 12.47B
ITCI Intracellular Th

N/A

USD 7.22B
LNTH Lantheus Holdings Inc

N/A

USD 5.61B
ALKS Alkermes Plc

N/A

USD 4.13B
ALVO Alvotech

N/A

USD 3.81B
HCM HUTCHMED DRC

N/A

USD 3.18B
INDV Indivior PLC Ordinary Shares

N/A

USD 2.22B
AMPH Amphastar P

N/A

USD 1.96B
EVO Evotec SE ADR

N/A

USD 1.74B

ETFs Containing DCPH

QQQS Invesco NASDAQ Future Gen.. 0.82 % 0.00 %

N/A

USD 8.10M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.65% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.65% 93% A 93% A
Trailing 12 Months  
Capital Gain 77.34% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.34% 93% A 94% A
Trailing 5 Years  
Capital Gain 19.36% 82% B 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.36% 82% B 60% D-
Average Annual (5 Year Horizon)  
Capital Gain -3.03% 50% F 38% F
Dividend Return -3.03% 50% F 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.60% 39% F 28% F
Risk Adjusted Return -5.08% 51% F 38% F
Market Capitalization 2.21B 89% A- 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector